Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective biomarker study of patients with metastatic castration-resistant
prostate cancer (mCRPC) undergoing sequential treatment with docetaxel and enzalutamide. The
participants will undergo serial pre- and post-therapy blood collection for biomarker
analysis as part of the primary objective of the study. The primary goal of this study is to
evaluate the association of the AR-V7 status and androgen receptor (AR) gene alterations with
PSA response to docetaxel and enzalutamide.